Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Completed · Phase 2

Conditions studied: Amyloidosis

In brief

OBJECTIVES: I. Determine the response, disease-free survival, and overall survival of patients with primary light chain amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. II. Determine the toxicity of this regimen in these patients.

Key facts

Study ID

NCT00017680

Run by

Herbert Irving Comprehensive Cancer Center

People needed

25

Starts

1999-07-01

Expected to finish

2004-04-01

Last updated by the study team

2008-06-09

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Herbert Irving Comprehensive Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.